MISSION Therapeutics
Mission Therapeutics discovers and develops small molecule drugs that selectively inhibit deubiquitylating enzymes (DUBs) to treat serious diseases. The company's lead clinical candidates, MTX325 and MTX652, target the USP30 enzyme to enhance mitophagy for the treatment of Parkinson’s disease, kidney disease, and heart failure. Its platform focuses on translating ubiquitin pathway research into therapies for neurodegenerative conditions, fibrosis, and rare mitochondrial diseases.
Biotechnology
Life Sciences
Pharmaceuticals
Healthtech
Funding summary
- Total raised
- €51.4M
- Funding rounds
- 5
Investors in MISSION Therapeutics
Investors on record for MISSION Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like MISSION Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors